Big Pharma Split Stock Market Value
| PRM Stock | CAD 13.12 0.01 0.08% |
| Symbol | Big |
Big Pharma Split Price To Book Ratio
Big Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Big Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Big Pharma.
| 10/30/2024 |
| 11/29/2024 |
If you would invest 0.00 in Big Pharma on October 30, 2024 and sell it all today you would earn a total of 0.00 from holding Big Pharma Split or generate 0.0% return on investment in Big Pharma over 30 days. Big Pharma is related to or competes with Sustainable Power, Global Dividend, Brompton Lifeco, Prime Dividend, and Real Estate. Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc More
Big Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Big Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Big Pharma Split upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.27) | |||
| Maximum Drawdown | 5.23 | |||
| Value At Risk | (2.27) | |||
| Potential Upside | 1.54 |
Big Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Big Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Big Pharma's standard deviation. In reality, there are many statistical measures that can use Big Pharma historical prices to predict the future Big Pharma's volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | 11.46 |
Big Pharma Split Backtested Returns
Big Pharma Split secures Sharpe Ratio (or Efficiency) of -0.16, which signifies that the company had a -0.16% return per unit of standard deviation over the last 3 months. Big Pharma Split exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Big Pharma's risk adjusted performance of (0.11), and Mean Deviation of 0.6479 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.0132, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Big Pharma are expected to decrease at a much lower rate. During the bear market, Big Pharma is likely to outperform the market. At this point, Big Pharma Split has a negative expected return of -0.16%. Please make sure to confirm Big Pharma's kurtosis, and the relationship between the maximum drawdown and day median price , to decide if Big Pharma Split performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.07 |
Virtually no predictability
Big Pharma Split has virtually no predictability. Overlapping area represents the amount of predictability between Big Pharma time series from 30th of October 2024 to 14th of November 2024 and 14th of November 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Big Pharma Split price movement. The serial correlation of 0.07 indicates that barely 7.0% of current Big Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.07 | |
| Spearman Rank Test | -0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Big Pharma Split lagged returns against current returns
Autocorrelation, which is Big Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Big Pharma's stock expected returns. We can calculate the autocorrelation of Big Pharma returns to help us make a trade decision. For example, suppose you find that Big Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Big Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Big Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Big Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Big Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
Big Pharma Lagged Returns
When evaluating Big Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Big Pharma stock have on its future price. Big Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Big Pharma autocorrelation shows the relationship between Big Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in Big Pharma Split.
Regressed Prices |
| Timeline |
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Big Stock
Moving against Big Stock
The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.